 Home > Active Ingredient News > Blood System > Junshi Bio: The clinical trial application of JS103 injection was approved

Junshi Bio: The clinical trial application of JS103 injection was approved

 Last Update: 2021-05-23
 Source: Internet
 Author: User

Tags

mayer china value

national graduation products

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On May 12, Junshi Biologics announced that it received the "Notice of Drug Clinical Trial Approval" approved and issued by the National Medical Products Administration, and the clinical trial application for JS103 injection was approved.

It is reported that JS103 is a pegylated uricase derivative independently developed by the company.

Or without the treatment of gout, it can reduce blood uric acid by catalyzing the oxidation of uric acid into allantoin, which has a significantly higher solubility than uric acid .
Hyperuricemia is a metabolic disorder due to the excessive purine or urinary uric acid excretion blocked, causing the blood uric acid value is formed over a critical metabolic syndrome abnormalities.
Gout is a crystal-associated joint disease caused by monosodium urate deposition and is directly related to hyperuricemia.
According to "China high urinary acidosis and gout treatment guidelines (2019)" shows that China hyperuricemia overall prevalence was 13.
3%, gout was 1.
1%, from hyperuricemia and gout due to high incidence of related diseases in China One of the chronic diseases of JS103 , so the development of JS103 is expected to bring more treatment options to patients.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.